Kailos Genetics Paves the Way for Low-Cost Genetic Testing with $99 Full Panel

Limited time pricing for full panel gives consumers greater access
to affordable genetic testing so they can make more informed decisions
about their health

, a personalized medicine information company offering
leading-edge gene-based testing, today announced the release of
PGxComplete, a comprehensive, full panel, gene-based test offered at $99
through November 30, 2015 – a test that traditionally sells for hundreds
or even thousands of dollars. By further reducing their already low cost
full panel test, Kailos is able to give consumers greater access to
affordable genetic testing, ultimately giving them the power to make
more informed decisions about their health.

The full panel tests 20 different classes of medications to reveal how
one’s body responds to more than 50 types of medications, including
antidepressants, opioids, HIV/AIDS treatment and cancer therapy. By
understanding how one’s body metabolizes these medicines, each person
can take greater control over their own health – helping to avoid
overdose, select the most effective medications and receive the desired
results from treatment.

“It’s our goal to give people the ability to understand how medicine
will work for them before it is prescribed,” said Troy Moore, chief
scientific officer of Kailos Genetics. “With full panel testing, people
are able to see how they respond to a variety of medications catered to
their lifestyle and needs. Whether someone is preparing for surgery,
recovering from a heart attack or managing their cancer treatment, we
want them to have the information necessary to make informed treatment

PGxComplete gives people the tools needed to work with their physician
to select the right medication and dosage combination based on their
DNA. This helps ensure that they are getting the desired effects of
treatment. A list of medicines tested through PGxComplete includes:

  • Antiarrythmics: Digoxin, Flecainide and Propafenone
  • Anticoagulants: Warfarin
  • Antidepressants: Tri-cyclics, SSRIs and SNRIs
  • Antidiabetics: Repaglinide
  • Antiepileptics: Mephenytoin, Pheytoin and Valproic Acid
  • Antihypertensives: Losartan and Metoprolol
  • Chemotherapeutics: Capecitabine, Cisplatin, Cyclophosphamide,
    Fluorouracil, Methotrexate, Paclitaxel and Tamoxifen
  • Corticosteroids: Prednisone
  • HIV/AIDS Treatments: Efavirenz, Nelfinavir and NEvirapine
  • Immunosuppressants: Cyclosporine, Mercaptourine, Sirolimus and
  • Muscle Relaxants: Carisoprodol and Diazapam
  • NSAIDs, Celecoxib and Diclofenac
  • Opioids: Buprenorphine, Codeine, Hydrocodone, Oxycodone and
  • Platelet Aggregation Inhibitors: Clopidogrel
  • Proton Pump Inhibitors: Lansoprazole, Omeprazole and
  • Statins: Atorvastatin, Pravastain, Rosuvastatin and Simvastatin
  • Thrombophilia: Risk factor for blood clot development

Kailos Genetics developed the PGxComplete test using advanced technology
that harnesses DNA sequencing and enables a more holistic view of a
person’s gene-based medical information. Kailos’ mission is to help
consumers, their families and their physicians to make informed
decisions about their health at a fraction of the cost and without a
complex collection process. As a part of this mission, all genetic tests
are currently discounted for a limited time to increase accessibility
and affordability for consumers.

Learn more about PGxComplete by visiting https://www.kailosgenetics.com/pgxcomplete.

About Kailos

Kailos Genetics is a trusted provider of personalized health
information. Addressing unmet needs of healthcare consumers and their
families is Kailos’ primary reason for being. With its proprietary and
robust DNA sequencing enrichment and laboratory information system,
TargetRichTM, Kailos helps make personalized medicine
affordable and accessible for everyone through the Kailos test. Founded
in 2010, and based in Huntsville’s HudsonAlpha Institute for
Biotechnology, Kailos is committed to providing a simple, trusted and
affordable way to help individuals understand what’s in their genes. To
learn more, visit www.kailosgenetics.com/about-kailos.


Dodge Communications
Christina Kendall, 770-576-2545